Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03170206
Previous Study | Return to List | Next Study

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03170206
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : April 24, 2020
Sponsor:
Collaborators:
Pfizer
Array BioPharma
Information provided by (Responsible Party):
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Tracking Information
First Submitted Date  ICMJE May 19, 2017
First Posted Date  ICMJE May 30, 2017
Last Update Posted Date April 24, 2020
Actual Study Start Date  ICMJE May 31, 2017
Estimated Primary Completion Date June 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
  • Maximum Tolerated Dose [ Time Frame: 2 years ]
    A standard 3+3 design will be implemented to discover the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the combination of study drugs. A dose will be declared the MTD if zero or 1 patient out of 6 experience a dose limiting toxicity (DLT) at the highest dose level below the maximally administered dose. This is generally the Recommended Phase 2 dose- RP2D
  • Safety and tolerability of Palbocilib and Binimetinib [ Time Frame: 2 Years ]
    Toxicities will be graded using version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE).
  • progression free survival [ Time Frame: 4 months ]
    Determine the proportion of patients who are alive and progression-free at 4 months in the binimetinib, palbociclib and combination arms.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
  • Pharmacokinetics [ Time Frame: 15 days ]
    The pharmacokinetic properties-Cmax maximum plasma concentration for the combination of palbociclib and PD-0325901 will be evaluated utilizing serial blood draws on cycle 1 day 1 and a steady state trough level drawn on cycle 1 day 15.
  • Target engagement of palbociclib and binimetinib [ Time Frame: 2 years ]
    Confirm target engagement of palbociclib and binimetinib in pre- and on-treatment tumor biopsies from patients enrolled to an MTD expansion cohort.
  • Objective Response [ Time Frame: 2 years ]
    Determine the best objective response rate, as determined by RECIST 1.1, of the combination of palbociclib and binimetinib, palbociclib alone and binimetinib alone in patients with advanced KRAS mutant NSCLC.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Official Title  ICMJE Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Brief Summary

This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.

The drugs involved in this study are:

  • Palbociclib
  • Binimetinib
Detailed Description

This research study is a Phase I/II clinical trial. Participants are being asked to participate in the Phase I portion of the study. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.

Palbociclib is an oral drug which has been shown to stop the cell cycle, which is the way a cell initiates growth. Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow. By putting these two drugs together the investigators hope that it will have a greater affect on cancer growth than either drug alone. The FDA (the U.S. Food and Drug Administration) has not approved binimetinib as a treatment for any disease. The FDA has not approved palbociclib for use in lung cancer but it has been approved for other cancer types.

The purpose of this study is to:

  • Test the combination of these two drugs, Palbociclib and Binimetinib, in order to determine a safe and tolerable dose of the combination
  • Determine the response rate of the combination
  • Further evaluate the safety and side effect profile for the combination of palbociclib and binimetinib.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Phase 1 is a single group standard 3+3 dose escalation Phase 2 is a 3 arms randonmization
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lung Cancer
Intervention  ICMJE
  • Drug: Binimetinib
    Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
    Other Name: MEK162
  • Drug: Palbociclib
    It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
    Other Name: IBRANCE
Study Arms  ICMJE
  • Experimental: Binimetinib Combine with Palbociclib Phase 1
    • Palbociclib will be administered orally once daily
    • Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
    • Binimetinib will be administered orally twice daily
    • Patients will be dosed with Binimetinib continuously through the four weeks per cycle
    Interventions:
    • Drug: Binimetinib
    • Drug: Palbociclib
  • Experimental: Binimetinib Combine with Palbociclib Phase 2
    • Palbociclib will be administered orally once daily
    • Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
    • Binimetinib will be administered orally twice daily
    • Patients will be dosed with Binimetinib continuously through the four weeks per cycle
    Interventions:
    • Drug: Binimetinib
    • Drug: Palbociclib
  • Experimental: Binimetinib Phase 2
    • Binimetinib will be administered orally twice daily
    • Patients will be dosed with Binimetinib continuously through the four weeks per cycle
    Intervention: Drug: Binimetinib
  • Experimental: Palbociclib Phase 2
    • Palbociclib will be administered orally once daily
    • Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
    Intervention: Drug: Palbociclib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 25, 2017)
72
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2024
Estimated Primary Completion Date June 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any CLIA-certified method) for which curable treatment modalities are not an option
  • Part I Dose Escalation: Participants are required to have measurable disease per RECIST 1.1 within 4 weeks of study entry
  • MTD Expansion and Part II: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan. See section 10 for the evaluation of measureable disease.
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available in participants < 18 years of age, children are excluded from this study
  • Participants are permitted to have any number of prior therapies prior to enrollment
  • ECOG performance status < 2 (see Appendix A).
  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count > 1,500mm3
    • Hemoglobin > 9 g/dL
    • Platelets > 100,000/mcL
    • Total bilirubin < 2 X institutional upper limit of normal (ULN)
    • AST (SGOT)/ALT (SGPT) < 2.5 X ULN -OR-
    • AST (SGOT)/ALT (SGPT) < 5.0 X ULN if hepatic metastases are present
    • Creatinine < 1.5 X the institutional ULN -OR-
    • Calculated creatinine clearance (determined as per Cockcroft-Gault) > 50 mL/min
  • The effects of palbociclib and binimetinib on the developing human fetus are not fully known. For this reason, women of child-bearing potential and men must agree to use adequate contraception (combination hormonal and barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after discontinuation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.
  • The availability of archival tissue to evaluate retrospectively the participant's Rb status. The requirement is a minimum of 5 unstained slides with each tissue cut measuring 4 microns in width. Ideally 15 slides will be requested. Patients without available archival tissue may be enrolled at the discretion of the principal investigator.
  • Patients must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments (excluding neuropathy which can be ≤ Grade 2, and alopecia).
  • MTD Expansion: Patients must be willing to undergo pre- and on-treatment tumor biopsies. Patients are exempt from this requirement if, in the opinion of the investigator, the biopsy procedure would pose a significant risk or if they have only pulmonary metastatic disease.
  • Patients must be able to take oral medications.
  • Patients must have adequate cardiac function, defined as:

    • Left ventricular ejection fraction (LVEF) > 50% as determined by echocardiogram or multigated acquisition scan (MUGA).
    • QTc < 480 msec.

Exclusion Criteria:

  • Participants who have had chemotherapy, radiotherapy, or major surgery within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
  • Participants receiving any other study agents concurrently with the study drugs.
  • Participants with symptomatic brain metastases that require chronic steroids. Patients with a history of brain metastases are permitted to enroll as long as they have been treated, are off of steroids, and have been stable for a minimum of one month on imaging.
  • MTD Expansion: Patients currently taking anticoagulants and who cannot safely hold the medication to facilitate pre and on-treatment tumor biopsies are excluded from participation.
  • Concurrent use of strong CYP3A4 inhibitors/inducers is prohibited due to drug-drug interactions with palbociclib. Moderate CYP3A4 inhibitors/inducers should be used with caution (see Appendix C).
  • Part I Dose Escalation: Concurrent use of proton-pump inhibitors (PPIs) is prohibited.
  • Uncontrolled intercurrent illness including, but not limited to:

    • ongoing or active infection requiring systemic treatment
    • symptomatic congestive heart failure
    • cardiac arrhythmia
    • psychiatric illness/social situations that would limit compliance with study requirements
    • hypertension, defined as systolic blood pressure > 160 mmHg despite medical management
    • myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting < 6 months prior to screening
  • History of QT syndrome, Brugada syndrome, known history of QTc prolongation, or Torsades de Pointes.
  • History of Gilbert's syndrome.
  • History of neuromuscular disorders that are associated with elevated CK (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • History of other malignancy which could affect compliance with the protocol or interpretation of results. History of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are allowed. Subjects with a malignancy that has been treated with curative intent will also be allowed if the malignancy has been in remission without treatment for ≥ 2 years prior to Cycle 1, Day 1. Subjects with localized prostate cancer that has been treated with curative intent will be allowed
  • Patients planning to embark on a new strenuous exercise regimen after the first dose of study treatment.
  • History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigator.
  • Pregnant women are excluded from this study because the study agents have the potential for teratogenic or abortifacient effects. As there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding must be discontinued if the mother is treated.
  • Part II: Individuals with a history of a different malignancy are ineligible except for the following circumstances:

    • They have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
    • Individuals with the following cancers are eligible if diagnosed and curatively treated within the past 5 years: cervical cancer in situ, and basal or squamous cell carcinoma of the skin.
  • Known HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Patients with known active hepatitis B and/or active hepatitis C infection.
  • Evidence of visible retinal pathology on screening ophthalmologic examination that places the participant at an unacceptable risk for retinal vein occlusion (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, etc.).
  • History of retinal degenerative disease.
  • Presence of neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration on screening ophthalmologic exam.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Geoffrey Shapiro, MD, PhD 617-632-4942 geoffrey_shapiro@dfci.harvard.edu
Contact: Andrew Wolanski, NP 617-632-6623 andrew_wolanski@dfci.harvard.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03170206
Other Study ID Numbers  ICMJE 16-531
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute
Study Sponsor  ICMJE Dana-Farber Cancer Institute
Collaborators  ICMJE
  • Pfizer
  • Array BioPharma
Investigators  ICMJE
Principal Investigator: Geoffrey Shapiro, MD, PhD Dana-Farber Cancer Institute
PRS Account Dana-Farber Cancer Institute
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP